Akin Advised Pharmakon in its Debt Financing for Optinose’s Sale to Paratek Pharmaceuticals
Contact:
(New York and Washington, D.C.) – Akin advised Pharmakon Advisors, LP and its investment funds in providing, alongside other lenders including funds managed by Oaktree Capital Management, L.P., debt financing for, among other things, the acquisition of Optinose, Inc., and its product, XHANCE® (fluticasone propionate), by Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers. In connection with the consummation of the acquisition, Optinose, Inc. terminated and repaid in full all of its outstanding obligations due to Pharmakon and its investment funds under its secured term loan.
The Akin team was led by tax partner Geoffrey Secol and included associates Jake Gawlak and Yossi Abadi. Additional support was provided by tax partners Stuart Leblang and David Snyder; health care & life sciences partners Nate Brown and Kelly Cleary; and associate John Kwack.
For additional information on the transaction, please click here.
Akin is a leading international law firm with more than 900 lawyers in offices throughout the United States, Europe, Asia and the Middle East.
# # #
People Mentioned in This News
